MM
Malignant melanoma (MM) patients undergoing phase II-randomized chemoimmunotherapy trials were treated with DTIC, IFNalpha (Hoffmann-La Roche) (group A, n = 31), and with DTIC, IFNalpha and 13-cis-RA (Isotretinoin, Hoffmann-La Roche, Basel, Switzerland) (group B, n = 29).
<span class="disease" id="17973783-2-0-18">Malignant melanoma</span> (<span class="disease" id="17973783-2-20-22">MM</span>) patients undergoing phase II-randomized chemoimmunotherapy trials were treated with DTIC, <span class="gene" id="17973783-2-114-122">IFNalpha</span> (Hoffmann-La Roche) (group A, n = 31), and with DTIC, <span class="gene" id="17973783-2-177-185">IFNalpha</span> and 13-cis-RA (Isotretinoin, Hoffmann-La Roche, Basel, Switzerland) (group B, n = 29).